Retinopathy: Golgi and Breye join forces
Milan-based biotech incubator Golgi Neurosciences is teaming up with Danish biopharma Breye Therapeutics to develop the P2X7 receptor antagonist programme for the treatment of retinal disorders.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 238 entries already.
Entries by Uta Mommert
Recordati bags EUSA to strengthen rare disease franchise
Italian pharma company Recordati is putting €750m on the table to acquire UK-based specialty pharmaceutical company EUSA Pharma.
Sanofi acquires therapeutic acne vaccine
Sanofi is strengthening its vaccine business by acquiring an Austrian company. The French pharma group is taking over skin disease specialist Origrimm Biotechnology.
Quell raises US$156m for Treg cell therapy programme
Quell Therapeutics has raised a whopping US$156m from a prestigious investor group in an oversubscribed Series B financing. With the funds, the British biotech wants to hasten its CAR-Treg cell therapy candidate on its way to the clinic.
Vaccibody – now Nykode – in vaccine deal with Regeneron
Vaccibody rebrands as Nykode Therapeutics and teams up with Regeneron in a vaccine deal potentially worth US$925m.
Vifor buys out one-drug wonder Sanifit
Swiss Vifor Pharma is shelling out more than €375m for Mallorca-based Sanifit, a clinical-stage cardio-renal biopharmaceutical company with a single compound in development.
Synthace bags US$35m for R&D cloud platform
London-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors.
EU orders up Valneva’s inactivated Covid-19 vaccine
The EU has secured 60 million doses of Valneva’s potential Covid-19 vaccine VLA2001. When approvied, it would be the first inactivated vaccine on the EU market.
Stock market boom: Two biotechs go public
Two European oncology biopharma companies have made the leap onto the stock market: French MaaT Pharma went public on Euronext Paris, while Danish IO Biotech chose Nasdaq Global Market for its IPO.
LSP raises a whopping €850m for the European life sciences
European life science investor LSP has raised €850m for its 7th generation flagship fund LSP 7.